Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate‐specific antigen ( PSA ) concentration in the F innish prostate cancer screening trial
- 7 June 2013
- journal article
- clinical trial
- Published by Wiley in BJU International
- Vol. 112 (6) , 735-741
Abstract
Objective: To assess whether histological signs of inflammation are associated with an increased risk of subsequent prostate cancer ( PCa ) in men with elevated serum prostate‐specific antigen ( PSA ) concentrations and benign initial biopsy. Materials and Methods: Study subjects were men aged 54–67 years with an elevated PSA (≥4 ng/mL or 3–4 ng/mL and free to total PSA ratio ≤0.16 or positive digital rectal examination), but a benign biopsy result within the F innish population‐based randomised screening trial for PCa , which started in 1996. A total of 293 prostate biopsies without PCa or suspicion of malignancy from the first screening round in the T ampere centre were re‐evaluated by a uropathologist to assess histological inflammation. Results of the subsequent screening rounds were obtained from the trial database and PCa diagnoses made outside the screening were obtained from the F innish C ancer R egistry. The median length of follow‐up was 10.5 years. Cox regression analysis was used to assess PCa risk after the initial benign biopsy. Results: Histological inflammation was found in 66% of the biopsies. Subjects with inflammation at the biopsy had a slightly lower PCa risk in the second screening round (18 vs 27%, rate ratio 0.69, 95% confidence interval [ CI ] 0.35–1.34) relative to men without inflammation. In further follow‐up, the PCa risk remained nonsignificantly lower (hazard ratio [ HR ] 0.71, CI 0.46–1.10; P = 0.13). The risk was not appreciably affected by adjustment for age, PSA , prostate volume and family history of PCa ( HR 0.67, CI 0.42–1.07; P = 0.092). Conclusions: Histological inflammation in a prostate biopsy among men with an initial false‐positive screening test was not associated with an increased risk of subsequent PCa , but instead with a decreased risk which was of borderline significance. Inflammation in prostate biopsy is not a useful risk indicator in PCa screening.Keywords
This publication has 33 references indexed in Scilit:
- Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trialsBMJ, 2010
- Test Sensitivity in the European Prostate Cancer Screening Trial: Results from Finland, Sweden, and the NetherlandsCancer Epidemiology, Biomarkers & Prevention, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or LowerJAMA, 2005
- Interval Carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-RotterdamJNCI: Journal of the National Cancer Institute, 2003
- Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific AntigenNew England Journal of Medicine, 2003
- Meta-Analysis of Prostate-Specific Antigen and Digital Rectal Examination as Screening Tests for Prostate CarcinomaThe Journal of the American Board of Family Medicine, 2003
- Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasiaThe Prostate, 1994
- Serum Prostate Specific Antigen as Pre-Screening Test for Prostate CancerJournal of Urology, 1992
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987